ArticleMolecular biology reports2025
Specnuezhenide mitigates tunicamycin-induced liver injury in mice via ER stress modulation and metabolic reprogramming.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDrug-induced liver injury (DILI) is a major health concern, often linked to endoplasmic reticulum (ER) stress. Specnuezhenide (SPE), a bioactive iridoid glycoside from Ligustrum lucidum, is known for its hepatoprotective effects, but its role in ER stress-mediated DILI remains unclear. This study investigated the protective mechanisms of SPE against tunicamycin (TM)-induced liver injury, focusing on ER stress and metabolic reprogramming.
methodsMale C57BL/6 mice were pretreated with SPE (40, 80, or 160 mg/kg) or the positive control 4-phenylbutyric acid (PBA) for seven days, followed by a single intraperitoneal injection of TM (1 mg/kg) to induce acute liver injury. Liver injury, lipid profiles, histopathology, ER stress markers, insulin signaling, lipid and cholesterol metabolism, and markers of inflammation and oxidative stress were evaluated.
resultsSPE pretreatment significantly alleviated TM-induced liver injury, as indicated by reduced serum ALT and AST levels, decreased liver weight, and improved hepatic histopathology. Mechanistically, SPE inhibited activation of the PERK/eIF2α/CHOP axis of the unfolded protein response (UPR), restored metabolic homeostasis by enhancing hepatic insulin sensitivity via the AKT/GSK3β/mTOR pathway, normalized lipid and cholesterol metabolism gene expression, and reduced hepatic steatosis. SPE also attenuated hepatic inflammation and oxidative stress.
conclusionsSpecnuezhenide protects against TM-induced liver injury through multiple mechanisms, including suppression of ER stress, restoration of metabolic homeostasis, and reduction of inflammation and oxidative stress. Therefore, these findings highlight SPE as a promising therapeutic candidate for DILI.
Indexed as
Identifiers
40788369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.